Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates
Authors:
- 1 October 1996
- journal article
- Published by Elsevier in Brain Research
- Vol. 735 (2) , 298-306
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Is striatal dopaminergic receptor imbalance responsible for levodopa‐induced dyskinesia?Fundamental & Clinical Pharmacology, 1995
- Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's diseaseMovement Disorders, 1995
- Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of toleranceMovement Disorders, 1995
- SUBCUTANEOUS LISURIDE INFUSION IN PARKINSON'S DISEASEBrain, 1991
- D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal NeuronsScience, 1990
- Nigrostriatal Damage is Required for Induction of Dyskinesias by l-DOPA in Squirrel MonkeysClinical Neuropharmacology, 1990
- Increased Binding of [3H]Muscimol and [3H]Flunitrazepam in the Rat Brain Under HypoxiaJournal of Neurochemistry, 1988
- Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonismAnnals of Neurology, 1988
- COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPAThe Lancet, 1982
- Intermittent versus continuous stimulation: Effect of time interval on the development of sensitization or toleranceLife Sciences, 1980